Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Interview: Mereo All Set For Key Setrusumab Data

Aug 16 2019

• By Kevin Grogan

Q4 2019 — End of the year will be pivotal for Mereo • Source: Shutterstock

Related Content

Pfizer Grows In Rare Disease With $810m Dwarfism Company Buy

May 09 2019

Ipsen Commercial Chief: Buying Clementia Will Bolster Rare Disease Franchise

Feb 25 2019

Ultragenyx Gets Second Drug Approval; Crysvita With Kyowa Hakko Kirin

Apr 18 2018

Related Companies

Mereo BioPharma Group plc

Novartis AG

Ipsen SA

Clementia Pharmaceuticals, Inc.

Pfizer Inc.

TherAchon AG

Ultragenyx Pharmaceutical Inc.

AstraZeneca PLC

GSK plc

Boehringer Ingelheim GmbH

OncoMed Pharmaceuticals, Inc.

Additional Topics

Strategy Rare Diseases Clinical Trials Research & Development Orthopedics BioPharmaceutical

More from Musculoskeletal

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.